Skip to main content
Premium Trial:

Request an Annual Quote

Precision Antibody Completes SBIR Contract to Generate Antibodies for SISCAPA Assays


NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

Under the contract, Precision generated an unspecific number of new mouse monoclonal antibodies for use in SISCAPA mass spec assays.

SISCAPA uses antibody-based capture of target peptides prior to mass spec analysis to increase the sensitivity and throughput of traditional selected-reaction monitoring assays. As such, a catalogue of high-quality antibodies to peptide targets is key to the technology's utility.

Precision generated the antibodies using its proprietary Affinity Boost, SMART Fusion, and SeleKDt technologies, which, it said, enabled antibodies with higher affinity and lower off-rates than typical mouse monoclonals.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.